TrialSignal
Clinical trial intelligence report
A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT02024308-Jul 28, 2026
NCT ID
NCT02024308
Status
UNKNOWN
Phase
PHASE4
Sponsor
Changhai Hospital
Executive brief
Investment-Ready Snapshot
A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia is a PHASE4 clinical asset sponsored by Changhai Hospital in Acute Myeloid Leukemia, AML1-ETO Fusion Protein Expression. SEO and diligence focus: Fludarabine, Cytarabine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02024308
Indication
Acute Myeloid Leukemia
Modality
combination therapy
Target
Fludarabine, Cytarabine
Intervention
Fludarabine, Cytarabine
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.